Investigational long-acting acylated amylin analogue
Cagrilintide — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
Investigational
- No approved United States product in Drugs@FDA as of this review.
- ClinicalTrials.gov returned 44 registered studies with cagrilintide as an intervention at review, including the Phase 3 REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519) trials of cagrilintide with semaglutide.
- Not interchangeable with pramlintide, the earlier approved amylin analogue.
- Not named on the WADA 2026 Prohibited List.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built